Clinical Trials Logo

Chronic Lymphocytic Leukemia clinical trials

View clinical trials related to Chronic Lymphocytic Leukemia.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05521178 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Cardiotoxicities in Patients Receiving BTKi

Start date: May 2024
Phase:
Study type: Observational

This is a multicenter, prospective, observational cohort study to comprehensively and longitudinally evaluate and characterizes the cardiovascular events with CLL patients who are initiating treatment with a Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or acalabrutinib.

NCT ID: NCT05465876 Withdrawn - COVID-19 Clinical Trials

Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL

PACE-CLL
Start date: October 2023
Phase: Phase 2
Study type: Interventional

Chronic lymphocytic leukaemia (CLL) is a common lymphoid malignancy affecting older adults. CLL patients are immunocompromised by the disease itself and by several of its therapies. It has now been shown that many CLL patients do not mount an antibody response following COVID-19 vaccination and are therefore at risk of COVID-19 infection. Furthermore, patients with hematologic malignancies are known to be at increased risk of severe infection if they do acquire COVID-19 infection. The purpose of this trial is to document evidence of passive immunity to COVID-19 infection after EVUSHELD administration with serologic and neutralization assays at multiple post administration time points in patients with no response to standard of care vaccination to COVID-19. This trial will include a single dose of EVUSHELD to be administered, with a 1-year follow-up period, comprising of 8 health status visits. Blood samples will be taken at screening, baseline and at multiple health status visits over the course of the year for various antibody testing and analysis. T cell reactivity to COVID-19 epitopes will be studied at baseline and again monthly for 3 months in any participants that become infected with COVID-19.

NCT ID: NCT05037669 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

Start date: July 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I trial to assess the safety and feasibility of administering pre-manufactured allogeneic T cells from healthy donors expressing CD19-targeting chimeric antigen receptors lacking expression of HLA class I, HLA class II molecules and endogenous TCR through CRISPR-mediated genome-editing of beta-2 microglobulin, CIITA and T cell receptor alpha chain, respectively. These cells are called PACE CART19 cells.

NCT ID: NCT04694560 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Start date: December 22, 2020
Phase:
Study type: Observational

The purpose of this study is to find out whether people with CLL or SLL who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or partial remission of their disease.

NCT ID: NCT04665115 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Start date: November 23, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects of ibrutinib in treating patients with B-cell malignancies who are infected with COVID-19. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ibrutinib is a first in class Bruton tyrosine kinase inhibitor (BTKi), for the treatment of B-cell malignancies. This study is being done to determine if taking ibrutinib after contracting COVID-19 will make symptoms better or worse.

NCT ID: NCT04660045 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Early Intervention With Acalabrutinib in Patients With High Risk CLL

Start date: May 2022
Phase: Phase 2
Study type: Interventional

This study evaluates the effectiveness of acalabrutinib treatment in patients with chronic lymphocytic leukemia (CLL) deemed at high risk for Richter's Transformation (RT). This is a single arm study. Enrolled patients will initiate therapy with acalabrutinib and will dose continuously. While on study, subjects will be monitored monthly for the first 3 months, then every three months thereafter until disease progression, discontinuation due to toxicity, death, or study completion.

NCT ID: NCT04282174 Withdrawn - Clinical trials for Acute Myeloid Leukemia

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

2019-KOE-001
Start date: September 2022
Phase: Phase 2
Study type: Interventional

This is a Phase II trial testing disease-specific myeloablative conditioning regimens for preparatory cytoreduction of patients receiving allogeneic HLA-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells (PBSC) depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system. The CliniMACS Fractionation system is a method that positively selects CD34+ progenitor cells from PBSC by immunoadsorption of cells binding on anti CD34 monoclonal antibody to paramagnetic beads, which can then be isolated by passage through a magnetized column and released by agitation of beads. Two conditioning regimens have been used successfully with an alternative similar system, isolex, which is no longer being manufactured.

NCT ID: NCT04043845 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Start date: February 3, 2020
Phase: Phase 1
Study type: Interventional

This research is studying the safety of combining ibrutinib with the study drug LY3214996 for chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).

NCT ID: NCT03943342 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Start date: March 11, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well the combination of ibrutinib and venetoclax works in treating patients with chronic lymphocytic leukemia whose cancer has stopped responding to ibrutinib alone. Both ibrutinib and venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving ibrutinib and venetoclax together after development of ibrutinib resistance may work better than discontinuing ibrutinib and switching to other chemotherapy drugs.

NCT ID: NCT03639324 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

RIVe-CLL/SLL
Start date: October 2, 2020
Phase: Phase 1
Study type: Interventional

To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) following a lead-in period with idelalisib and rituximab